• Heparin Sodium as a Glycosaminoglycan Anticoagulant: Protoco

  2026-04-20

  Heparin sodium is a benchmark glycosaminoglycan anticoagulant empowering precise thrombosis and blood coagulation studies. Unlock its full potential for anti-factor Xa activity assays, nanoparticle-mediated delivery, and advanced aPTT measurement workflows—plus actionable troubleshooting and cross-domain insights informed by the latest exosome nanovesicle research.

• Cy5 maleimide (non-sulfonated): Practical Guide for Protein

  2026-04-20

  Cy5 maleimide (non-sulfonated) addresses site-specific fluorescent labeling of proteins via cysteine thiols, enabling robust probe generation for imaging and tracking applications. It is optimal for workflows requiring high selectivity and red-shifted detection but is not suited for targets lacking accessible thiols or requiring aqueous-only labeling conditions.

• Pterostilbene Protects the BBB After Ischemic Stroke via Cyt

  2026-04-19

  This study elucidates the multi-phase mechanism by which pterostilbene mitigates blood–brain barrier (BBB) dysfunction following cerebral ischemia/reperfusion injury. Through targeted cytoskeletal stabilization and basement membrane preservation, the research clarifies pterostilbene’s neuroprotective actions and highlights implications for therapeutic development in ischemic stroke.

• Adipose-Neural Axis Drives Cardiac Arrhythmias via Leptin-NP

  2026-04-18

  This study establishes the adipose-neural axis as a mechanistic driver of cardiac arrhythmias by demonstrating leptin-mediated activation of sympathetic neurons and subsequent NPY signaling. The findings provide a new framework for understanding arrhythmogenesis and inform future targeted intervention strategies.

• IGF2BP1 Drives Macrophage Glycolysis and Fibrosis via THBS1

  2026-04-17

  This study uncovers how the m6A reader IGF2BP1 promotes pulmonary fibrosis by stabilizing THBS1 mRNA, thereby enhancing macrophage glycolytic metabolism and fibrotic phenotype. The elucidation of the IGF2BP1/THBS1/TLR4 axis provides new mechanistic insight and potential intervention points for fibrosis research.

• 25-Hydroxycholesterol Drives Immunosuppressive Macrophage Me

  2026-04-16

  Xiao et al. (2024) uncover how tumor-associated macrophages (TAMs) accumulate 25-hydroxycholesterol (25HC), leading to lysosomal AMPK activation and STAT6-mediated immunosuppressive programming. Targeting the cholesterol-25-hydroxylase (CH25H)–25HC axis reprograms macrophage metabolism, enhances anti-tumor T cell responses, and synergizes with anti-PD-1 immunotherapy.

• Deferasirox as an Oral Iron Chelator: Protocols, Use Cases &

  2026-04-15

  Harness Deferasirox's unique iron chelation and signaling effects for advanced cancer research and iron overload models. This guide translates mechanistic insights and new lysosomal biology into stepwise experimental protocols, troubleshooting, and beyond-bench applications.

• DiscoveryProbe Metabolism-related Compound Library: Advanced

  2026-04-14

  The DiscoveryProbe™ Metabolism-related Compound Library offers an unmatched platform for dissecting metabolic pathways, enabling researchers to perform robust, reproducible metabolic enzyme inhibition assays and pathway modulation studies. Backed by stringent QC and literature-driven workflow strategies, this library accelerates metabolism and cancer biology research with high-throughput precision.

• Ferroptosis and NRF2 Disruption in FDXR Disease: Mechanistic

  2026-04-13

  This study identifies ferroptosis, driven by NRF2 pathway disruption, as a key mechanism in mitochondrial disease linked to FDXR mutations. These findings clarify the role of mitochondrial iron overload and offer new directions for therapeutic intervention in disorders involving aberrant iron metabolism.

• Belinostat (PXD101): Reliable HDAC Inhibition for Cancer Ass

  2026-04-13

  This article delivers scenario-driven, evidence-based guidance for researchers using Belinostat (PXD101) (SKU A4096) in cell viability, proliferation, and cytotoxicity assays. By addressing real laboratory challenges with quantitative data and best practices, it demonstrates how APExBIO’s Belinostat (PXD101) empowers reproducible, sensitive epigenetic cancer research workflows.

• Diphenyleneiodonium Chloride: Precision Tool for cAMP & Redo

  2026-04-12

  Diphenyleneiodonium chloride (DPI) empowers researchers to interrogate cAMP signaling and redox enzyme function with unrivaled specificity and reproducibility. This comprehensive guide delivers protocol insights, advanced applications, and actionable troubleshooting strategies for maximizing DPI's utility in oxidative stress and signal transduction research.

• NUAK1/2 Inhibition Lowers p-tau Ser356 in Alzheimer’s Models

  2026-04-12

  This study establishes that phosphorylation of tau at Ser356, mediated by NUAK1, is closely associated with Alzheimer’s disease progression and neurofibrillary tangle formation. Using the selective NUAK1/2 inhibitor WZ4003, the authors demonstrate effective reduction of p-tau Ser356 in ex vivo brain slice models, highlighting a promising avenue for targeted tauopathy research.

• Methyl-β-cyclodextrin: Practical Guidance for Membrane Studi

  2026-04-11

  Methyl-β-cyclodextrin (SKU C6939) addresses the need for precise, reproducible extraction of cholesterol and modulation of membrane organization in cell-based assays. Its high solubility and purity make it suitable for workflows targeting lipid raft disruption and membrane cholesterol extraction, but it is not intended for diagnostic or medical use. Researchers should adhere to recommended storage and handling protocols to maintain reagent efficacy.

• IWP-2: Precision Wnt Production Inhibitor for Advanced Assay

  2026-04-11

  IWP-2, a potent Wnt production inhibitor from APExBIO, delivers unparalleled control over Wnt/β-catenin signaling for cancer and regenerative biology research. This guide demystifies applied workflows, protocol tweaks, and troubleshooting strategies to unlock reproducible insights in challenging models such as the gastric cancer cell line MKN28 and primary epithelial systems.

• Elacridar hydrochloride: Practical Guidance for Efflux Inhib

  2026-04-10

  Elacridar hydrochloride (GF 120918A) is a research compound widely used to inhibit breast cancer resistance protein (BCRP) and P-glycoprotein (P-GP), key multidrug transporters that limit the brain and oral bioavailability of many therapeutics. Its primary application is in enhancing drug delivery across biological barriers in experimental workflows. Elacridar hydrochloride is not intended for diagnostic or clinical use and should not be used outside controlled research settings.

15733 records 1/1049 page Next 12345 下5页 Last page